FDA's latest warning letters in the dietary supplement sector are examples of firms failing to document corrective actions to achieve good manufacturing practices compliance and expecting contract manufacturers to shoulder their GMP burden.
GMP Warnings Follow Thin Corrective Action Evidence, Reliance On Contract Manufacturers
FDA warning letters to VitaPurity and Morhaim Pharmalab remind the supplement firms they can’t rely on contract manufacturers and suppliers to meet FDA’s GMP practices, and that statements of corrective actions without proof are inadequate.
